Introduction
============

We aimed to evaluate evidence from randomised controlled trials (RCTs) investigating the effect of systemic corticosteroids in adults with community-acquired pneumonia (CAP). Observational data suggest that corticosteroids may decrease mortality in severe CAP \[[@B1]\], and several large RCTs have been published since the recent Cochrane review \[[@B2]\].

Methods
=======

A systematic review of the literature: Cochrane Central Register for Controlled Clinical Trials, MEDLINE, EMBASE and SCOPUS, and reference lists of original studies and reviews. Data were collated and analysed using Review Manager v5.1.

Results
=======

A total of 254 RCTs were identified. Seven met inclusion criteria, totalling 806 patients. Studies varied in methodology, participants, interventions, and outcome measures. Where meta-analysis was possible, data are presented in Table [1](#T1){ref-type="table"} (outcomes: hospital mortality, 30-day mortality, hospital length of stay, superinfection, hyperglycaemia). Excepting hyperglycaemia, effect estimates were not statistically significant. Two small studies (*n*= 46 and *n*= 30) concentrated on severe CAP (using ATS and BTS criteria); one study found a statistically significant reduction in mortality, lengths of stay and duration of mechanical ventilation in the steroid group, but similar improvements in the other study, and in a large subgroup of patients with severe CAP in another study (*n*= 93) were not found. Significant reductions in inflammatory markers in the week following initiation of steroid treatment were found in six studies.

###### 

Meta-analysis of clinical outcomes

  Outcome              Number of studies   Population   Effect
  -------------------- ------------------- ------------ -----------
  Hospital mortality   5                   537          OR 0.65
  30-day mortality     3                   562          OR 0.90
  Hospital LOS         2                   244          MD -1.52
  Superinfection       3                   563          OR 1.24
  Hyperglycaemia       2                   517          OR 2.69\*

LOS, length of stay. \**P*\< 0.0001.

Conclusion
==========

Systemic corticosteroid administration as adjunctive treatment for CAP does not appear to improve relevant clinical outcomes, regardless of severity, and is associated with significantly increased incidence of hyperglycaemia.
